![Bioniq, founded in 2019 and renowned for its personalized supplements based on blood biomarker data, today announced the close of its $15M Series B funding round. The oversubscribed round was led by Principal Investors HV Capital and Unbound, both leading European VCs. The company is valued at $75M and will use the funds to further expand its global market share through continued disruption of the dietary supplements market.](https://startuprise.co.uk/wp-content/uploads/2024/07/Bioniq.webp)
Bioniq, founded in 2019 and renowned for its personalized supplements based on blood biomarker data, today announced the close of its $15M Series B funding round. The oversubscribed round was led by Principal Investors HV Capital and Unbound, both leading European VCs. The company is valued at $75M and will use the funds to further expand its global market share through continued disruption of the dietary supplements market.
Bioniq will focus on product development including global laboratory network integrations, market, operational, and human resources expansion in the U.S. and the Middle East, and implementing a corporate platform for medical, wellness, and athletic institutions.
Read also - One Data funding news – Germany-based One Data Secures €32 Million in Series B Extension Round Funding
RECOMMENDED FOR YOU
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/01/Hamburg-based-Startup-airfocus-Secures-a-7.5-Million-in-Funding.webp)
[Funding alert] Hamburg-based airfocus Secures a $7.5 Million in Funding
Startup Rise EU
Jan 12, 2024
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/02/NYC-based-BuildStock-Secures-1.6Million-in-Pre-Seed-Funding-4.webp)
[Funding alert] Paris-based Ouinex Secures over $4Million in Funding
Startup Rise EU
Feb 23, 2024
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/02/London-based-Greyparrot-Secures-12.8Million-in-Funding.webp)
[Funding alert] London-based Greyparrot Secures $12.8Million in Funding
Team SR
Feb 12, 2024
Bioniq GO utilizes the company’s same proprietary database to offer users a more accessible option, based on a questionnaire that prompts the AI algorithm to recommend users with a unique supplement blend based on their responses and previous users’ blood biomarker data.
"We've entered a new era in nutritional supplementation over the last six years, where it’s become clear that one-size-fits-all solutions are simply inefficient,” said Vadim Fedotov, co-founder and CEO of Bioniq. “Everyone's health journey is unique and fluid. Customers need advanced, adaptable products that provide evolving support for personal health goals. Our AI-driven approach and extensive biochemical database allow us to create customized supplements that provide quantifiable results and cater to individuals’ specific needs. Beyond meeting consumer demand, we’re setting a new standard in the industry by making the process and results transparent to the users."
All of Bioniq’s supplements are Swiss-made, pharmaceutical-grade and utilize precise micro-dosing to address bio-individual needs and deficiencies. Each formula is created specifically for an individual user and features a unique mix of antioxidants, vitamins, minerals, phytonutrients, amino acids and prebiotic fiber. Rather than traditional pills and capsules, the product is delivered in patented prebiotic guar granules, which are designed to mimic the way the body digests food, minimizing nutrient competition and maximizing bioavailability.
"Bioniq's exceptional growth is a testament to its innovative approach for high quality personalized health solutions that professional athletes across the world rely on” said David Kuczek, General Partner at HV Capital. “With sales from across 60 countries with the majority coming from North America, the most important market for health solutions globally, Bioniq is well-positioned to continue its trajectory of rapid expansion."
About Bioniq
Bioniq, launched in 2019 in London, UK, is the industry leader in offering AI-driven personalized supplements based on blood test data. After conducting years of testing, Bioniq has developed the largest of its kind proprietary biochemical database with blood test data from customers across 5 continents. Shipping globally, Bioniq has created unique formulas for over 100,000 users that incorporate components and dosages tailor-made to each individual’s nutrient deficiencies, as identified through their blood results.